Danaher Corporation — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request identifies 2022 Q4, this filing reports full-year results; it does not provide a clear standalone fourth-quarter summary in the supplied text. Danaher operates across Biotechnology, Life Sciences, Diagnostics, and Environmental & Applied Solutions, with products and services spanning biopharmaceutical production, research, diagnostics, water quality, and product identification.
Key financial results
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $31.47 billion | $29.45 billion |
| GAAP revenue growth | 7.0% | 32.0% |
| Core sales growth (non-GAAP) | 9.5% | 23.0% |
| Gross profit / gross margin | $18.95 billion / 60.2% | $17.95 billion / 61.0% |
| Operating profit / operating margin | $8.69 billion / 27.6% | $7.47 billion / 25.3% |
| Net earnings from continuing operations | $7.21 billion | $6.35 billion |
| Diluted EPS from continuing operations | $9.66 | $8.50 |
| Operating cash flow | $8.52 billion | $8.36 billion |
| Capital expenditures | $1.15 billion | $1.29 billion |
| Cash and equivalents at year-end | $6.00 billion | $2.59 billion |
| Total debt at year-end | $19.68 billion | $22.18 billion |
Operating cash flow less capital expenditures was approximately $7.37 billion in 2022 (calculated from reported figures). Net debt was approximately $13.68 billion, also calculated from reported cash and total debt. The current portion of debt was $591 million; approximately $2.0 billion of euro commercial paper due within a year was classified as long-term because Danaher said it had the intent and ability to refinance it.
Segment performance
| Segment | 2022 revenue | Revenue growth | Operating margin |
|---|---|---|---|
| Biotechnology | $8.76 billion | 2.0% | 34.3% |
| Life Sciences | $7.04 billion | 10.0% | 20.1% |
| Diagnostics | $10.85 billion | 10.0% | 31.7% |
| Environmental & Applied Solutions | $4.83 billion | 4.0% | 23.5% |
Revenue growth and segment figures are reported on a GAAP basis unless specified. Danaher realigned its reportable segments in Q4 2022 and restated prior-period segment data to match the new presentation.
Material changes versus FY2021
- Reported revenue rose 7.0%, while core sales grew 9.5%; currency translation reduced reported growth by 4.0 percentage points, and acquisitions contributed 1.5 points.
- Operating margin increased to 27.6% from 25.3%, partly because FY2021 included a $547 million contract-settlement expense related to a modified commercial arrangement and litigation resolution. Danaher identified this prior-year item as a 185-basis-point benefit to the year-over-year margin comparison.
- Gross margin declined to 60.2% from 61.0%, reflecting higher material, transportation, labor, restructuring and productivity-improvement costs, as well as a Russia-related inventory charge.
- Net earnings increased, supported by higher sales, a lower effective tax rate, and the absence of the 2021 contract-settlement charge; 2022 investment losses partly offset these benefits. Other income/expense moved from $456 million of income in 2021 to $226 million of expense in 2022, primarily reflecting investment losses.
- Operating cash flow increased 2%; working-capital uses were higher. Cash paid for acquisitions fell to $637 million from $10.96 billion, while total debt declined by approximately $2.50 billion.
Outlook, commentary, risks, and unusual items
- Management outlook: Danaher expected demand for products supporting COVID-19 testing and COVID-19 vaccine and therapy development to decrease in 2023. The company forecast a 2023 effective tax rate of approximately 19.5% and capital expenditures of approximately $1.5 billion. At December 31, 2022 exchange rates, management said 2023 sales would be essentially flat relative to 2022; a stronger U.S. dollar would adversely affect sales and results.
- Business drivers and pressures: Non-COVID bioprocessing demand was strong, while COVID-related bioprocessing demand declined. Diagnostics growth benefited significantly from COVID-19 molecular tests. Supply-chain shortages, inflation, shipping delays and labor constraints continued in 2022; Danaher said pricing and productivity measures largely mitigated their profitability impact, but future effects remained uncertain.
- EAS separation: Danaher announced plans to spin off Environmental & Applied Solutions, targeting completion in Q4 2023. The transaction was conditional on board approval, financing, tax opinions, IRS rulings and other approvals, and was not assured to close on schedule or at all.
- Russia-Ukraine conflict: Danaher suspended most shipments to Russia, with exceptions for products used to diagnose and treat patients and produce vaccines and therapeutics. It recorded a $43 million pretax charge in 2022, primarily for receivable and inventory impairments and contractual obligations.
- Tax matters: The IRS proposed adjustments that would increase taxable income by approximately $2.5 billion for 2016–2018 concerning deferral of certain self-insurance premium income. Danaher said it would defend its position. Danish tax assessments were approximately DKK 2.1 billion, or $298 million at year-end exchange rates; management said it did not expect resolution to have a future material adverse impact. Gross unrecognized tax benefits were approximately $1.1 billion.
- Other exposures: Reported risks include regulation and product approvals, competition and pricing, acquisition integration and goodwill/intangible impairment, cybersecurity and privacy, foreign exchange, supply-chain disruption, litigation, environmental matters, and debt and refinancing access. Environmental reserves were $197 million; management said excess amounts were not reasonably expected to have a material effect based on information available.
- Other financial items: The effective tax rate was 13.1% versus 16.5% in 2021, with 2022 benefiting from discrete tax items not expected to recur fully. Foreign-currency translation reduced comprehensive income; the 2022 translation loss was approximately $2.1 billion. No goodwill impairment was recorded in 2022.
Most important facts for investors to verify
- Whether 2023 demand normalization in COVID-related products and China’s healthcare activity affected reported growth, margins, and segment trends as management anticipated.
- Whether the EAS separation closed as planned, including transaction financing, tax treatment, separation costs, and any impact on Danaher’s continuing businesses.
- The eventual outcomes and cash or earnings effects of the IRS and Danish tax matters, and movements in unrecognized tax benefits.
- Whether pricing, productivity and supply-chain actions offset persistent cost inflation, and how working capital converts into cash.
- Debt maturities, commercial-paper refinancing availability, and liquidity after planned capital spending, dividends, acquisitions, and any separation-related financing.
- How investment valuations and the reported investment losses affect earnings, and whether segment comparisons remain comparable after the 2022 realignment.